| Bioactivity | Afasevikumab (RG 7624; RO 5553110; NI-1401) is a fully human monoclonal IgG1κ antibody neutralizing both IL-17A and IL-17F. Afasevikumab has anti-inflammatory activities[1]. |
| Invitro | Afasevikumab 由 N 末端 IL-17F 特异性部分、结合 IL-17A 和 IL-17F 的 a-C 末端部分以及结合人血清白蛋白的中心部分组成[1]。 |
| Name | Afasevikumab |
| CAS | 1589503-30-9 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Andrea Chiricozzi, et al. Emerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis: evaluating bimekizumab and its therapeutic potential. Psoriasis (Auckl). 2019 May 24;9:29-35. |